Skip to main content
. 2024 May 20;9:132. doi: 10.1038/s41392-024-01823-2

Table 12.

The FDA-approved and clinically developed epigenetic reprogramming inhibitor in cancer therapies

Type Drug Highest Phase Indications Company/Identifier Status
DNMTi Azacitidine (Vidaza) Approved Acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndromes Celgene /
Decitabine (Dacogen) Approved Acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndromes MGI Pharma & SuperGen /
Guadecitabine III Acute myeloid leukemia NCT02920008 Completed
III Myelodysplastic syndromes, leukemia myelomonocytic chronic NCT02907359 Completed
III Leukemia myeloid acute NCT02348489 Completed
NTX-301 I Acute myeloid leukemia, myelodysplastic syndromes, chronic myelomonocytic leukemia NCT04167917 Recruiting
MG98 I Unspecified adult solid tumor NCT00003890 Completed
HDACi Belinostat (Beleodaq) Approved Peripheral T-cell lymphoma Spectrum Pharma /
Panobinostat (Farydak) Approved Multiple myeloma Novartis /
Romidepsin (Istodax) Approved Cutaneous T cell lymphoma Gloucester Pharma /
Vorinostat (Zolinza) Approved Cutaneous T cell lymphoma Merk Sharp
Abexinostat III Renal cell carcinoma NCT03592472 Recruiting
ACY-241 I Multiple myeloma NCT02400242 Active, not recruiting
I Malignant melanoma NCT02935790 Completed
I Advanced solid tumors NCT02551185 Completed
I Non-small cell lung cancer NCT02635061 Active, not recruiting
AR-42 III Neurofibromatosis type 2 NCT05130866 Recruiting
CUDC-907 II Relapsed and/or refractory diffuse large B-cell lymphoma including myc alterations NCT02674750 Completed
II Thyroid neoplasms, poorly differentiated and undifferentiated thyroid cancer, differentiated thyroid cancer NCT03002623 Terminated
II Prostate cancer NCT02913131 Terminated
CXD101 II Colorectal neoplasms malignant NCT03993626 Unknown
II Diffuse large B-cell lymphoma NCT03873025 Withdrawn
II Hepatocellular carcinoma NCT05873244 Recruiting
Entinostat III Advanced breast cancer NCT03538171 Unknown
III Breast adenocarcinoma, HER2/Neu negative locally advanced breast carcinoma, metastatic breast carcinoma, recurrent breast carcinoma NCT02115282 Active, not recruiting
Givinostat (ITF2357) II Multiple myeloma NCT00792506 Terminated
II Chronic myeloproliferative neoplasms NCT01761968 Active, not recruiting
II Hodgkin’s lymphoma NCT00496431 Terminated
II Hodgkin’s lymphoma NCT00792467 Completed
Mocetinostat (MGCD0103) II Urothelial carcinoma NCT02236195 Completed
II Lymphocytic leukemia chronic NCT00431873 Completed
II Hodgkin’s lymphoma NCT00358982 Terminated
II Lymphoma NCT00359086 Completed
II Myelogenous leukemia acute, myelodysplastic syndromes NCT00374296 Terminated
II Lymphoma relapsed and refractory, diffuse large B-cell lymphoma and follicular lymphoma NCT02282358 Terminated
II Myelodysplastic syndrome, acute myelogenous leukemia NCT00324220 Completed
Resminostat (4SC-201) II Hepatocellular carcinoma NCT00943449 Completed
II Advanced colorectal carcinoma NCT01277406 Completed
II Hepatocellular carcinoma NCT02400788 Completed
II Hodgkin’s lymphoma NCT01037478 Completed
II Lymphoma NCT02953301 Active, not recruiting
Ricolinostat (ACY-1215) II Multiple myeloma NCT01997840 Active, not recruiting
II Lymphoma, Lymphoid malignancies NCT02091063 Completed
II Multiple myeloma NCT01323751 Completed
EZH2i Tazemetostat Approved Epithelioid sarcoma Epizyme /
GSK126 I Cancer, Neoplasms NCT02082977 Terminated
CPI-1205 II Metastatic castration-resistant prostate cancer NCT03480646 Unknown
CPI-1205 I Advanced solid tumors NCT03525795 Terminated
CPI-1205 I B-cell lymphoma NCT02395601 Terminated
DOT1Li Pinometostat (EPZ-5676)- II Recurrent/refractory acute myeloid leukemia NCT03701295 Completed
II Acute myeloid leukemia NCT03724084 Terminated
LSD1i ORY-1001 I Small cell lung cancer NCT02913443 Completed
I Acute myeloid leukemia NCT05546580 Recruiting
INCB059872 II Solid tumors and hematologic malignancy NCT02712905 Terminated
II Solid tumors NCT02959437 Terminated
II Myeloproliferative neoplasms, myelodysplastic syndrome NCT04061421 Recruiting
IMG-7289 II Acute myeloid leukemia NCT02842827 Completed
II Myelofibrosis NCT03136185 Completed
II Thrombocythemia NCT04081220 Recruiting
I Acute myeloid leukemia NCT05597306 Recruiting
II Extensive stage lung small cell carcinoma NCT05191797 Recruiting
GSK2879552 I Carcinoma small cell NCT02034123 Terminated
I Leukemia myelocytic acute NCT02177812 Terminated
CC-90011 I Lymphoma NCT02875223 Active, not recruiting
I Small cell lung carcinoma NCT03850067 Active, not recruiting
II Neoplasms NCT04350463 Active, not recruiting
I Prostatic neoplasms NCT04628988 Completed
I Leukemia NCT04748848 Terminated
SP-2577 II Ewing sarcoma NCT05266196 Enrolling by invitation
II Recurrent chronic myelomonocytic leukemia NCT04734990 Active, not recruiting
BETi TEN‐010 I Acute myeloid leukemia, myelodysplastic syndromes NCT02308761 Completed
I Multiple myeloma NCT03068351 Completed
I Solid tumors NCT01987362 Completed
GSK525762 II Neoplasms NCT01943851 Completed
I NUT midline carcinoma NCT01587703 Completed
OTX105 I Acute myeloid leukemia NCT01713582 Completed
I NUT midline carcinoma NCT02259114 Completed
CPI-0610 I Multiple myeloma NCT02157636 Completed
I Lymphoma NCT01949883 Completed

Source: All the information is derived from ClinicalTrials.gov (https://www.clinicaltrials.gov) and the United States Food and Drug Administration.gov (https://www.fda.gov/)